Experimental pharmacokinetics of a new antiparkinsonian drug ADK-1113-Reference-Cited by-同舟云学术

Experimental pharmacokinetics of a new antiparkinsonian drug ADK-1113

Published:2024-06-25 Issue:1 Volume: Page:27-31
ISSN:2686-8830
Container-title:Pharmacokinetics and Pharmacodynamics
language:
Short-container-title:Fk&Fd

Author:

Kravtsova O. Yu.¹^ORCID,Dvoryaninov D. A.¹,Kolyvanov G. B.¹^ORCID,Litvin A. A.¹^ORCID,Gribakina O. G.¹^ORCID,Zherdev V. P.¹^ORCID

Affiliation:

1. FSBSI «Federal research center for innovator and emerging biomedical and pharmaceutical technologies»

Abstract

The pharmacokinetics of a new antiparkinsonian drug ADK-1113 after single intravenous and intragastric administrations in mice at doses of 10 and 20 mg/kg was studied. The absolute bioavailability was 10.1–16.3 % that indicates on potential possibility of preparing a dosage form for oral administration.

Publisher

Publishing House OKI

Reference9 articles.

1. Kapitsa IG, Voronina TA. Antiparkinsonicheskaya aktivnost adamantylnogo proizvodnogo benzimidazola ADK-1113. Exper. Clin. Pharmacol. 2023;86(11S):68-68. (In Russ.). doi: 10/30906/ekf-2023-86s-68a.

2. Ragshaniya A, Kumar V, Tittal RK, Lal K. Nascent pharmacological advancement in adamantane derivatives. Arch Pharm (Weinheim). 2024 Mar;357(3):e2300595. doi: 10.1002/ardp.202300595.

3. Guidelines for conducting preclinical studies of drugs. Part one. Metodicheskie rekomendacii po provedeniyu doklinicheskih issledovanij farmakokinetiki novyh lekarstvennyh sredstv. Mironov AN. Moscow: Grif and K, 2012. P. 865-880. (In Russ.)

4. Kravtsova OYu, Dvoryaninov DA, Kolyvanov GB, et al. Quantification of a new antiparkinsonian agent ADK-1113 in mouse blood plasma by high performance liquid chromatography – tandem mass spectrometry. Exper. Clin. Pharmacol. 2024;87(2):6-12. (In Russ.). doi: 10/30906/0869-2092-2024-87-2-6-12.

5. Osnovy farmacokinetiki. Miroshnichenko II. Geotar-Med. Moscow: 2002 (In Russ.). ISBN 5-9231-0211-0.